IL6 and COVID-19: In severe COVID-19, the ‘negative regulation of the insulin receptor pathway, inferred as a possible cause of IL-6 signalling and inflammatory responses, can lead to ‘insulin resistance’ and ‘increasing blood glucose level’ (Fig. 6).